Benedetta P.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Efficacy and Safety of Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib in ER+/HER2- Advanced Breast Cancer with ESR1 Mutation
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Data & Insights
Has run more than one trial at 78 of 290 partner sites.
Specializations
Thoracic Oncology
Clinical activity is centered on non-small cell lung cancer, with interest in EGFR-mutated, ALK-positive, KRAS G12C, HER2-altered, and c-Met-positive disease, as well as locally advanced, metastatic, and resectable settings.
- Advanced and metastatic non-small cell lung cancer
- EGFR exon 20 insertion and other uncommon mutations
- Small cell lung cancer and pulmonary neuroendocrine carcinoma
- Pleural mesothelioma
The therapeutic focus includes targeted therapy, antibody-drug conjugates, and immunotherapy in lung and pleural malignancies.
Breast and Gynecologic Cancer
Research involvement extends to breast cancer, including HER2-positive, HER2-low, ER-positive, and ESR1-mutated disease, alongside ovarian, fallopian tube, primary peritoneal, and endometrial cancers.
- Early and metastatic breast cancer
- HER2-positive and HER2-negative endocrine-resistant disease
- Ovarian cancer and platinum-sensitive recurrence
- Endometrial cancer
Therapeutic interests include endocrine therapy, CDK4/6 inhibition, and novel antibody-based treatments for solid tumors.
Hematology and Blood Disorders
The investigator is active in acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and lymphoma, including aggressive and relapsed disease.
- Acute leukemias in pediatric and adult populations
- Chronic lymphocytic leukemia and small lymphocytic lymphoma
- Multiple myeloma
- Peripheral T-cell lymphoma and marginal zone lymphoma
Key therapeutic domains include novel targeted agents, BCL-2-directed treatment, and BTK inhibition in hematologic malignancies.
Cardiovascular and Thrombotic Disease
Clinical research also covers atherosclerotic cardiovascular disease, acute coronary syndrome, myocardial infarction, atrial fibrillation, stroke prevention, and venous thromboembolism.
- Secondary prevention after acute coronary events
- Stroke prevention in atrial fibrillation and post-ischemic events
- Thromboembolic risk reduction
- Inflammation-linked cardiovascular risk
The therapeutic emphasis includes antithrombotic strategies and cardiovascular risk modulation in high-risk patients.
Renal, Immune, and Metabolic Disorders
Additional activity includes chronic kidney disease, IgA nephropathy, kidney transplant rejection, multiple sclerosis, psoriasis, atopic dermatitis, and hemophilia, together with selected metabolic conditions.
- Glomerular and transplant-related kidney disease
- Relapsing and progressive multiple sclerosis
- Chronic spontaneous urticaria and inflammatory skin disease
- Hemophilia A and B
Therapeutic interests span immune modulation, renal protection, and replacement or prophylactic approaches for inherited bleeding disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.